Evidence map›Paper›PMID 42068514›Full record

ArticleClinical pharmacokinetics2026

Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study.

Anne Ravix, Yann Thoma, Annie Cathignol, Paul Thoueille, Catia Marzolini, Eric Giannoni, Thierry Buclin, Chantal Csajka, Kim Dao, Monia Guidi

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anne RavixCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Yann ThomaSchool of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Switzerland.
Annie CathignolSchool of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Switzerland.
Paul ThoueilleService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Catia MarzoliniService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Eric GiannoniService of Neonatology, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Thierry BuclinService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Chantal CsajkaCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Kim DaoService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Monia GuidiCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland. Monia.Guidi@chuv.ch.ORCID 0000-0002-6419-9317

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesTherapeutic drug monitoring (TDM) of vancomycin, ideally based on the ratio of the daily area under the curve to the minimal inhibitory concentration at steady state (AUC

methodsReference pharmacokinetic (PK) parameters and drug concentrations were simulated in NONMEM for 1000 virtual neonates using a published population PK model. Four TDM strategies were compared based on the percentage of patients achieving an AUC

resultsLess than 49% of patients reached the target with strategy 1, leading to frequent vancomycin overexposure. Strategy 2 enabled over 75% of patients to achieve AUC

conclusionThis virtual TDM study indicates that Bayesian MIPD optimizes vancomycin exposure in neonates, while simplifying the sampling strategy. This approach deserves to be integrated and validated in routine neonatal care.

Indexed as

Anti-Bacterial AgentsDrug MonitoringModels, BiologicalVancomycinArea Under CurveBayes TheoremComputer SimulationDose-Response Relationship, DrugFemaleHumansInfant, NewbornMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsVancomycin

Identifiers

PMID42068514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.